Predictive Markers of Response in a Phase II Trial of Axitinib in Advanced Melanoma
Description: 

This phase II study will consist of single agent axitinib in the treatment of patients with advanced melanoma. Response will be assessed after every 2 cycles and treatment will continue until disease progression or drug related harm to the patient.

Study Number: 

I 197811

Phase: 
II
Principal Investigator: 
ClinicalTrials.Gov ID: 
NCT01533948

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.